<DOC>
	<DOCNO>NCT02696941</DOCNO>
	<brief_summary>SGLT2 inhibitor proven effective several preclinical rodent model non-alcoholic fatty liver disease ( NAFLD ) . Using choline deficient diet recapitulate histological feature human non-alcoholic steatohepatitis ( NASH ) , find 5 week SGLT2 inhibition lead significant reduction hepatic triglyceride content improve marker liver fibrosis . Similarly , 4 week treatment obese mouse lead improve glucose tolerance , reduce hepatic steatosis reduce marker liver oxidative stress dose dependent manner . These finding correspond improvement traditional liver function test include aminotransferase ( ALT AST ) . The widely use antidiabetic agent metformin show rodent model increase hepatic insulin sensitivity lower liver fat content contrast finding human metformin increase hepatic insulin sensitivity , reduce body weight decrease liver fat content . The reason discrepancy animal human study , regard liver fat content remain unclear . The investigator hypothesise follow : - SGLT2 Inhibitors potential decrease lipid accumulation liver reduce de novo lipogenesis ( DNL ) - There decrease endogenous lipid synthesis ( DNL ) metformin thus change liver fat content . There two arm study . - Arm 1 : x10 participant poorly control type 2 Diabetes ( T2DM ) recommend start SGLT2 inhibitor call dapagliflozin recruit . - Arm 2 : x13 participant insulin resistance yet start diabetic medication recruit prescribed metformin standard clinical dos . The two arm run parallel participant undergo identical investigation 3 month treatment either dapagliflozin metformin . Investigations include liver magnetic resonance imaging/spectroscopy , fat biopsy , fat microdialysis sampling , two-step hyperinsulinaemic euglycaemic clamp , breath sample stable glucose palmitate isotope infusion . The investigator aim show SGLT2 inhibition decrease liver fat whereas aim demonstrate liver fat remain unchanged human , treat metformin . These data provide first evidence use SGLT2 inhibitor NAFLD , highly informative design future clinical study . Moreover , data gain metformin arm study provide first mechanistic evidence human effect metformin hepatic fatty acid metabolism .</brief_summary>
	<brief_title>SGLT2 Inhibitors Metformin Metabolism Non-Alcoholic SteatoHepatitis</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Arm 1 : SGLT2 inhibitor Volunteers diagnosis Type 2 Diabetes oral antidiabetic therapy stable dose ≥3 month include one following : i. Metformin monotherapy ii . Sulphonylurea monotherapy iii . Metformin Sulphonylurea dual therapy All volunteer due start SGLT2 inhibitor therapy inadequate glycaemic control prescribe accord licensed indication . Arm 2 : metformin • Insulin resistant treatment naive individual define fast insulin / glucose top 10th percentile Both arm : Participant willing able give inform consent participation study . Male Female , age 18 year 70 year . BMI : 2545 kg/m2 HbA1C : 4286mmol/mol Normal renal function Arm 1 : SGLT2 inhibitor Volunteers take insulin , glucagonlike peptide 1 analogue , thiazolidinediones , dipeptidyl peptidase IV inhibitor Arm 2 : metformin Volunteers take insulin , glucagonlike peptide 1 analogue , thiazolidinediones , SGLT2 inhibitor , metformin dipeptidyl peptidase IV inhibitor Both arm Age &lt; 18 &gt; 70 year Body mass index &lt; 25 &gt; 45kg/m2 A blood haemoglobin &lt; 120mg/dL History alcoholism great recommend alcohol intake ( Recommendations &gt; 21 drink average per week men &gt; 14 drink average per week woman ) Pregnant nurse mother History severe claustrophobia Presence metallic implant , pacemaker Haemorrhagic disorder Anticoagulant treatment History albumin allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>